Pathway Platform Purpose

Advancing insight-driven MetAP2 therapeutics to transform the lives of patients with complex metabolic disorders

Meet the Montillier family.
36-year-old Marc Montillier lives with
Prader-Willi syndrome.

Harnessing MetAP2 Inhibition

We are applying our proprietary understanding of the MetAP2 pathway to develop treatments for both rare and more prevalent complex metabolic disorders.

LEARN MORE

Addressing Complex Metabolic Disorders

We are committed to significantly improving the health and well-being of people affected by Prader-Willi syndrome, Type 2 diabetes and other metabolic conditions.

LEARN MORE

Living Our Purpose

Our team is inspired by patients, their families and caregivers, and we are committed to unlocking the value of MetAP2 inhibition to make a difference in their lives.

LEARN MORE